Carbaglu

Carglumic acid is an orphan drug used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency. This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and cause neurologic problems, cerebral edema, coma, and death. Carglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010.

Target : Other Targets

CAS Number : 1188-38-1

Formula Weight : 190.15

Molecular Formula : C6H10N2O5

Purity : >98%(HPLC)

Storage : (-20?)

Shipping Conditions : With Ice Pack

Stability : ? 2 years

Research use only, not for human use.